Advertisement

Topics

DARWIN 2 24-week monotherapy data in RA confirm previous results and support best-in-class potential for filgotinib

18:01 EDT 10 Aug 2015 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
ACR50 responses up to 45% as once-daily monotherapy DAS28(CRP) low disease activity up to 50% Similar efficacy  at 100 and 200 mg Safety profile in DARWIN 2 consistent with previous filgotinib RA studies These data complete the delivery ...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "DARWIN 2 24-week monotherapy data in RA confirm previous results and support best-in-class potential for filgotinib"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...